← All trials
NCT04707703
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Jan 13, 2021
- Last posted
- May 13, 2021
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San DiegoLead sponsor
- AstellasCollaborator
- University of California, San DiegoSponsor investigator
- University of California, San DiegoOverall official - principal investigator
- University of California, San DiegoStudy chair
- University of California, DavisStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.